| Literature DB >> 1340781 |
H J Guchelaar1, D R Uges, E G de Vries, J W Oosterhuis, N H Mulder.
Abstract
Although cisplatin is applied with success in clinical oncology, this success is limited because some cancers are initially unresponsive to cisplatin or become so during treatment. In this review, some strategies to overcome this problem are discussed. Among these are combination with the differentiation inducing agent, retinoic acid, combination with radiotherapy, and the use of hyperthermia.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1340781 DOI： 10.1016/s0936-6555(05)81134-3
Source DB: PubMed Journal: Clin Oncol (R Coll Radiol) ISSN： 0936-6555 Impact factor: 4.126